Physician profile
Michael C Young
NPI 1609864560
$10,582.61
in general payments reported to CMS, 2019-2025
40 companies · $2,315 in 2025
The $2,315 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $2,682 · 2021: $894 · 2022: $988 · 2023: $1,424 · 2024: $1,734 · 2025: $2,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,317 · Education: $133 · Consulting Fee: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,316.86 |
| Education | $133.26 |
| Consulting Fee | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $2,378.46 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,467.52 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $907.01 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $632.46 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Csl Behring | $504.96 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $504.42 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $423.25 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Amgen INC. | $381.05 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $372.67 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $348.70 | 2020-2025 | |
| Abbvie INC. | $298.31 | 2023-2025 | Rinvoq |
| Biocryst US Sales Co., LLC | $263.37 | 2022-2025 | Orladeyo |
| Genzyme Corporation | $228.50 | 2019-2025 | |
| Pharming Healthcare, INC. | $217.19 | 2023-2025 | Ruconest |
| Pfizer INC. | $200.21 | 2021-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $168.23 | 2020-2021 | |
| Kaleo, INC. | $137.69 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.45 | 2019-2023 | Spiriva Respimat |
| Blueprint Medicines Corporation | $116.33 | 2023-2025 | Ayvakit |
| Glaukos Corporation | $98.11 | 2025 | Kxl System (Not Refurbished) |
| Ionis Pharmaceuticals, INC. | $74.52 | 2025 | Dawnzera |
| Covis Pharma Gmbh | $72.95 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $68.56 | 2025 | Neffy |
| Alk-Abello, INC | $60.12 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Greer Laboratories, INC. | $54.47 | 2024-2025 | Palforzia |
| Verona Pharma, INC. | $49.28 | 2025 | Ohtuvayre |
| Incyte Corporation | $48.49 | 2021-2022 | |
| Gc Biopharma USA, INC. | $47.67 | 2025 | Alyglo |
| Octapharma USA, INC. | $44.62 | 2020 | |
| Shire North American Group INC | $43.01 | 2019 | |
| Merck Sharp & Dohme LLC | $36.52 | 2019 | |
| Dermavant Sciences, INC. | $28.96 | 2024 | Vtama |
| Hikma Pharmaceuticals USA | $27.16 | 2023-2024 | Ryaltris |
| Leo Pharma INC. | $25.89 | 2022 | |
| Phadia US INC. | $24.39 | 2024 | Immunocap |
| Cycle Pharmaceuticals INC | $23.80 | 2025 | Sajazir |
| Adma Biomanufacturing LLC | $23.32 | 2023-2025 | |
| Bio Products Laboratory USA, INC. | $20.44 | 2023 | Gammaplex, Coagadex |
| Invivyd INC | $17.69 | 2025 | Pemgarda |
| Uswm, LLC | $16.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.